No definition available.
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
520210 |
1. Apply sex-specific ruleNone |
520210 |
2. Check conditionsNone |
520210 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
207 |
4. Check minimum number of eventsNone |
207 |
5. Include endpointsNone |
207 |
6. Filter based on genotype QC (FinnGen only) |
207 |
Control definitions (FinnGen only)
- Control exclude
- AB1_INTESTINAL_INFECTIONS
Extra metadata
- Level in the ICD hierarchy
- 3
- First used in FinnGen datafreeze
- DF5
Similar endpoints
↥List of similar endpoints to
Amoebiasis
based on the number of shared cases.
Similar with more cases:
- Intestinal infectious diseases
- Certain infectious and parasitic diseases
- Any event in hilmo or specialist outpatient
- Any prescribed medicine buy
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 2264 | 1163 | 1084 |
| Only index persons | 1862 | 978 | 884 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.03 | 0.03 | 0.03 |
| Only index persons | 0.03 | 0.04 | 0.03 |
| Median age at first event (years) | |||
| Whole population | 35.75 | 39.01 | 31.87 |
| Only index persons | 35.28 | 37.77 | 32.54 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 207 | 119 | 88 |
| Unadjusted period prevalence (%) | 0.04 | 0.04 | 0.04 |
| Median age at first event (years) | 44.44 | 45.34 | 43.23 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 193
- Matched controls
- 1929
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
A06.9
ICD-10 Finland
Amoebiasis, unspecified
+∞
73.8
66
*
A06.0
ICD-10 Finland
Acute amoebic dysentery
+∞
47.9
44
*
A06.1
ICD-10 Finland
Chronic intestinal amoebiasis
+∞
27.8
26
*
A09
ICD-10 Finland
Other gastroenteritis and colitis of infectious and unspecified origin
8.0
19.9
48
77
A06.8
ICD-10 Finland
Amoebic infection of other sites
+∞
19.1
18
*
R10.4
ICD-10 Finland
Other and unspecified abdominal pain
3.4
14.0
94
421
P01AB01
ATC
metronidazole; oral, rectal
2.9
11.4
100
518
A08.4
ICD-10 Finland
Viral intestinal infection, unspecified
31.8
9.5
12
*
A06.4
ICD-10 Finland
Amoebic liver abscess
+∞
9.4
9
*
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
2.9
9.1
67
302
UJF32
NOMESCO Finland
Coloscopy
3.0
9.0
59
245
A07.8
ICD-10 Finland
Other specified protozoal intestinal diseases
+∞
8.4
8
*
00699
ICD-8 Finland
Amoebiasis, Without mention of liver abscess
+∞
8.4
8
*
A10AB01
ATC
insulin (human); parenteral (insulins and analog. for injection, fast-acting)
7.8
7.4
16
22
A04.7
ICD-10 Finland
Enterocolitis due to Clostridium difficile
+∞
7.3
7
*
A02BC02
ATC
pantoprazole; systemic
2.3
7.0
126
872
R50.9
ICD-10 Finland
Fever, unspecified
3.1
6.8
38
140
Z04.8
ICD-10 Finland
Examination and observation for other specified reasons
3.3
6.5
33
114
2500B
ICD-9 Finland
Diabetes mellitus without mention of complication[DIABETES MELLITUS SINE COMPLICATIONE ,TYYPPI I]
15.0
6.5
10
7
A10AA02
ATC
NA
8.6
6.4
13
16
R51.80
ICD-10 Finland
Headache
2.9
6.4
40
160
R11
ICD-10 Finland
Nausea and vomiting
4.1
6.4
24
65
N02AX02
ATC
tramadol; systemic, rectal
2.2
6.3
85
505
00920
ICD-8 Finland
Diarrhoeal disease, Gastroenteritis (acuta) (infectiosa)
+∞
6.3
6
*
H02AB07
ATC
prednisone; oral
3.2
6.2
32
113
A10AA01
ATC
NA
9.1
6.2
12
14
AA1AD
NOMESCO Finland
CT of head and brain
2.5
6.1
51
241
R06.0
ICD-10 Finland
Dyspnoea
2.4
6.0
55
272
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
45
56
9.99
35.15
3.6
1.7
—
—
—
0
0
45
163
3.25
10.02
1.9
3.2
4.4
7.5
umol/l
1.44
36
136
127
798
2.53
9.51
5.8
5.8
10.1
11.3
umol/l
1.31
119
749
105
625
2.38
8.59
5.6
4.3
36.5
36.3
g/l
0.11
95
591
110
706
2.19
7.10
7.7
6.4
1.2
1.2
mmol/l
0.18
103
651
52
251
2.43
6.56
3.0
2.5
1.0
0.7
e6/l
0.22
24
144
76
435
2.18
6.41
3.9
2.8
0.2
0.3
e6/l
0.14
53
320
102
655
2.10
6.37
2.6
2.2
75.7
77.4
nmol/l
0.22
95
580
49
235
2.42
6.25
3.0
2.6
1.5
2.5
e6/l
0.41
21
128
81
492
2.06
5.74
3.1
2.4
56.1
58.8
u/l
0.30
73
451
132
956
2.05
5.71
10.7
9.6
4.0
4.0
e9/l
0.04
113
830
33
139
2.63
5.48
3.9
5.5
2.1
2.2
mmol/l
0.06
28
109
24
85
3.06
5.46
1.9
1.5
—
—
—
0
0
82
511
2.00
5.34
3.5
3.2
30.5
28.5
u/l
0.43
77
488
16
44
3.86
5.32
1.4
1.1
—
—
—
0
0
87
557
1.97
5.22
4.2
2.9
—
—
—
0
0
112
782
1.94
5.19
8.6
6.6
1.2
1.2
mmol/l
0.84
96
658
16
45
3.77
5.16
1.4
1.1
—
—
—
0
0
75
461
1.98
5.02
1.9
2.1
134.2
328.0
u/l
0.76
67
433
32
142
2.48
4.77
3.9
5.4
6.1
5.9
kpa
0.43
32
137
47
251
2.13
4.56
1.9
1.7
1056.6
1285.2
nmol/l
1.02
38
187
65
393
1.95
4.49
4.2
2.8
9823.3
4983.2
umol/l
0.21
53
335
22
86
2.74
4.21
1.5
1.3
—
—
—
0
0
9
13
7.18
4.21
3.1
1.1
—
—
—
0
0
26
112
2.51
4.12
1.0
1.0
—
—
—
0
0
109
794
1.79
4.08
6.7
4.6
0.0
0.0
estimate
0.50
18
154
9
14
6.66
4.03
3.1
1.1
—
—
—
0
0
87
597
1.79
3.96
2.1
1.8
97.8
97.7
pmol/l
0.01
42
304
109
799
1.77
3.95
4.9
3.4
0.0
0.0
estimate
0.00
18
148
107
781
1.77
3.93
4.7
3.4
0.0
0.0
estimate
0.00
18
155
65
409
1.86
3.92
1.4
1.4
0.6
1.3
u/ml
1.52
11
104
27
122
2.40
3.87
10.2
9.5
2.0
1.1
mmol/l
0.47
27
117
157
1295
1.88
3.69
4.1
3.8
14.9
14.7
pmol/l
0.43
143
1170
79
544
1.73
3.46
3.5
2.9
2.3
2.4
mmol/l
0.38
65
479
47
277
1.90
3.43
2.8
2.9
2.4
2.4
mmol/l
0.63
40
243
151
1245
1.79
3.38
9.2
6.4
79.1
82.6
u/l
0.47
144
1156
5
5
10.20
2.99
1.2
1.0
—
—
—
0
0
186
1679
2.06
2.60
19.5
11.8
23.3
21.9
mg/l
0.21
157
1260
5
7
7.28
2.56
1.2
1.6
—
—
—
0
0
44
278
1.74
2.54
2.9
2.9
116.7
135.1
ng/l
0.09
33
206
26
139
2.00
2.50
2.5
2.4
0.2
0.2
g/l
0.10
20
130
5
8
6.37
2.38
1.2
1.0
92.2
97.5
%
—
5
8
9
28
3.31
2.33
1.3
1.6
—
—
—
0
0
47
311
1.66
2.28
1.6
1.7
431.9
469.1
pmol/l
0.33
40
260
53
368
1.59
2.12
2.3
2.0
2.5
2.9
mg/l
1.01
40
308
171
1542
1.63
1.90
5.4
4.5
1.7
2.7
mu/l
0.61
161
1396
112
928
1.45
1.88
6.9
5.1
6.9
6.6
mmol/l
0.63
107
847
19
101
1.97
1.88
7.4
8.7
24.7
25.1
mmol/l
0.10
19
101
50
353
1.55
1.85
2.5
2.2
—
—
—
0
0
8
29
2.83
1.81
1.0
1.3
—
—
—
0
0
48
340
1.54
1.75
1.6
1.9
0.9
1.1
mg/l
0.42
32
264
24
142
1.78
1.74
1.7
1.6
—
—
—
0
0
7
24
2.98
1.74
1.0
1.5
—
—
—
0
0
7
24
2.98
1.74
1.0
1.5
—
—
—
0
0
11
48
2.36
1.73
1.1
1.1
—
—
—
0
0
134
1160
1.44
1.71
3.3
3.3
—
—
—
0
0
58
430
1.48
1.71
5.7
3.7
0.0
0.0
estimate
0.50
18
152
10
43
2.39
1.63
1.4
1.5
—
—
—
0
0
5
14
3.63
1.62
1.2
1.0
—
—
—
0
0
49
357
1.49
1.56
1.6
1.7
—
—
—
0
0
87
716
1.37
1.40
3.1
2.5
117.0
101.4
ug/l
0.25
82
658
24
152
1.65
1.39
3.5
3.2
—
—
—
0
0
9
41
2.25
1.39
1.1
1.4
—
—
—
0
0
13
68
1.97
1.36
1.4
1.3
—
—
—
0
0
5
17
2.99
1.36
1.8
1.2
—
—
—
0
0
76
615
1.37
1.35
5.5
3.6
—
—
—
0
0
19
114
1.73
1.33
1.4
1.7
—
—
—
0
0
19
115
1.72
1.30
3.1
3.1
65.2
66.2
ml/min/173m2
—
8
49
11
56
2.02
1.24
1.3
2.7
—
—
—
0
0
10
49
2.09
1.24
1.2
1.3
—
—
—
0
0
5
19
2.67
1.22
1.8
1.2
—
—
—
0
0
169
1564
1.44
1.21
3.7
3.8
1.3
1.3
mmol/l
0.07
158
1431
22
142
1.61
1.20
1.8
1.5
—
—
—
0
0
5
20
2.54
1.16
2.2
1.2
—
—
—
0
0
5
20
2.54
1.16
1.8
1.2
—
—
—
0
0
5
20
2.54
1.16
2.2
1.2
—
—
—
0
0
5
20
2.54
1.16
2.2
1.2
—
—
—
0
0
5
20
2.54
1.16
1.8
1.2
—
—
—
0
0
53
415
1.37
1.14
1.9
1.6
1.5
1.4
mmol/l
0.51
48
346
16
96
1.72
1.14
5.1
3.2
5.2
5.2
kpa
0.20
16
86
39
290
1.42
1.13
1.4
1.3
32.9
25.9
iu/ml
—
8
101
86
727
1.31
1.11
4.9
4.0
—
—
—
0
0
168
1561
1.40
1.11
19.7
12.8
40.0
40.4
%
0.34
132
1182
5
21
2.41
1.09
1.4
1.7
—
—
—
0
0
7
34
2.09
1.04
3.9
3.4
45.7
25.5
mg/l
—
7
28
7
34
2.09
1.04
1.6
2.2
—
—
—
0
0
7
34
2.09
1.04
3.9
3.3
59.7
257.5
mg/l
—
7
28
22
149
1.53
1.00
12.8
11.7
-0.7
1.7
mmol/l
0.76
17
128
29
210
1.44
0.97
1.8
1.7
—
—
—
0
0
126
1134
1.28
0.97
3.3
2.9
55.9
46.9
u/l
0.46
120
1066
48
381
1.34
0.95
1.7
1.4
22.1
21.9
nmol/l
0.04
41
319
6
27
2.26
0.94
1.5
1.2
—
—
—
0
0
70
587
1.29
0.94
3.7
3.2
33.9
42.7
ng/l
0.29
53
398
13
79
1.69
0.90
2.8
4.9
0.9
1.4
%
1.92
13
79
15
95
1.62
0.90
1.3
1.6
—
—
—
0
0
6
30
2.03
0.87
1.0
1.2
—
—
—
0
0
160
1495
1.31
0.86
6.1
5.3
39.7
39.3
mmol/mol
0.19
150
1378
49
396
1.31
0.86
3.3
3.2
1214.6
1059.3
ng/l
0.13
42
330
6
31
1.96
0.85
1.5
1.8
—
—
—
0
0
15
98
1.57
0.81
17.9
9.7
1.2
1.5
%
0.62
15
98
15
98
1.57
0.81
17.9
10.1
0.7
0.7
%
0.22
15
98
6
33
1.84
0.79
1.5
1.8
—
—
—
0
0
5
24
2.11
0.75
1.6
1.8
—
—
—
0
0
7
38
1.87
0.74
1.6
1.4
—
—
—
0
0
12
76
1.61
0.73
1.3
2.1
6.5
3.1
mg/l
—
6
58
5
25
2.02
0.73
1.4
1.1
—
—
—
0
0
5
25
2.02
0.73
2.8
1.4
—
—
—
0
0
7
40
1.78
0.72
3.0
3.1
24.0
25.1
mmol/l
—
7
32
163
1542
1.27
0.68
17.5
11.1
84.3
83.9
ml/min/173m2
0.08
136
1253
14
95
1.51
0.66
1.6
1.3
—
—
—
0
0
5
29
1.74
0.64
2.0
1.3
—
—
—
0
0
185
1783
1.35
0.63
13.9
9.3
28.1
25.8
u/l
0.33
180
1715
27
211
1.32
0.61
1.9
1.7
1.5
1.4
%
0.23
22
188
35
284
1.28
0.61
1.5
1.3
3.7
12.3
u/ml
1.11
11
109
12
173
0.67
0.60
1.4
1.7
—
—
—
0
0
11
73
1.54
0.57
4.7
2.9
48.4
49.5
%
0.05
11
73
169
1628
1.21
0.45
4.5
4.2
4.6
4.7
mmol/l
0.27
158
1506
168
1618
1.20
0.44
4.5
4.1
1.5
1.5
mmol/l
0.11
158
1485
0
16
0.00
0.41
0.0
1.7
—
7.4
—
0
7
0
17
0.00
0.41
0.0
1.5
—
—
—
0
0
8
60
1.35
0.41
1.8
1.7
29.9
40.2
nmol/l
—
8
60
0
18
0.00
0.40
0.0
3.7
—
74.3
—
0
18
28
234
1.23
0.40
2.0
2.2
—
—
—
0
0
0
19
0.00
0.39
0.0
1.3
—
—
—
0
0
26
218
1.22
0.36
1.8
2.1
—
—
—
0
0
6
41
1.48
0.36
2.2
4.4
148.5
168.7
%
—
6
41
170
1651
1.17
0.33
5.0
4.6
2.7
2.8
mmol/l
0.28
160
1517
192
1884
1.26
0.32
27.8
17.9
133.6
136.3
g/l
1.76
192
1855
7
54
1.31
0.30
2.0
1.5
—
—
—
0
0
7
55
1.28
0.30
1.0
1.1
—
14.6
—
0
13
22
187
1.20
0.28
4.4
4.4
28.1
32.0
%
0.80
15
120
9
72
1.26
0.26
2.6
1.5
417.0
308.6
mu/l
—
9
67
29
255
1.16
0.26
1.5
1.5
—
—
—
0
0
0
11
0.00
0.21
0.0
4.3
—
—
—
0
0
0
10
0.00
0.21
0.0
1.3
—
—
—
0
0
0
10
0.00
0.21
0.0
1.2
—
—
—
0
0
30
270
1.13
0.20
3.5
2.8
0.6
0.7
ug/l
0.16
22
169
9
79
1.15
0.15
1.9
3.0
0.3
0.1
e6/l
—
9
73
15
132
1.15
0.13
1.7
2.2
3.4
5.8
ug/l
0.97
15
116
15
135
1.12
0.10
4.8
3.4
1.3
1.2
mmol/l
1.62
15
121
162
1600
1.06
0.09
4.4
4.2
6.0
5.8
mmol/l
0.87
144
1462
6
55
1.09
0.09
1.3
1.9
—
—
—
0
0
6
57
1.05
0.08
1.2
1.6
—
—
—
0
0
7
67
1.05
0.08
2.1
2.2
53.0
41.5
u/l
—
7
61
47
454
1.05
0.06
5.6
4.4
1.6
1.8
ug/l
0.23
42
394
38
365
1.05
0.06
4.0
4.0
25.1
22.9
%
0.24
16
163
19
181
1.05
0.03
14.2
6.1
—
—
—
0
0
0
5
0.00
0.00
0.0
4.4
—
154.1
—
0
5
0
5
0.00
0.00
0.0
1.8
—
—
—
0
0
0
7
0.00
0.00
0.0
3.7
—
—
—
0
0
0
8
0.00
0.00
0.0
2.3
—
—
—
0
0
0
7
0.00
0.00
0.0
1.1
—
—
—
0
0
5
51
0.98
0.00
1.2
1.8
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
0.00
0.0
1.3
—
—
—
0
0
0
7
0.00
0.00
0.0
1.3
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
0.00
0.0
3.0
—
56.8
—
0
8
0
7
0.00
0.00
0.0
3.7
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint AB1_AMOEBIASIS and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| AB1_AMOEBIASIS | 1.655 [1.34, 2.04] | < 0.001 |
| Birth year | 0.995 [0.99, 1.0] | 0.218 |
During the follow-up period (1.1.1998 — 31.12.2019), 241 out of 965 females with AB1_AMOEBIASIS died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| AB1_AMOEBIASIS | 1.981 [1.42, 2.76] | < 0.001 |
| Birth year | 0.987 [0.98, 1.0] | 0.007 |
During the follow-up period (1.1.1998 — 31.12.2019), 202 out of 870 males with AB1_AMOEBIASIS died.
Mortality risk
Mortality risk for people of age
years, who have AB1_AMOEBIASIS.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.174% | 0.37% |
| 5 | 0.862% | 2.264% |
| 10 | 2.187% | 5.55% |
| 15 | 4.515% | 10.558% |
| 20 | 7.752% | 17.621% |
Relationships between endpoints
↥Index endpoint: AB1_AMOEBIASIS – Amoebiasis
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data